LYB LyondellBasell

FY2025 10-K
Filed: Feb 20, 2026
Health Care
Industrial Organic ChemicalsSEC EDGAR

LyondellBasell (LYB) filed its fiscal year 2025 10-K annual report with the SEC on Feb 20, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Management Discussion & Analysis

  • Revenue $30.15B in 2025, down 10% YoY (−$3.24B) due to lower prices (−8%) and volumes (−4%), offset by +2% FX impact
  • Operating loss $(420)M in 2025 vs operating income $1.92B in 2024; EBITDA $1.13B vs $3.46B, driven by impairments and margin compression
+3 more insights

Risk Factors

  • Regulatory risk from European oligomers divestiture, expected to close Q2 2026, may cause operational disruption and asset impairment charges
  • Geopolitical exposure in Middle East and South America risks raw material supply disruptions due to political instability and civil unrest
+3 more insights

Financial Summary
XBRL

Revenue

$30.2B

Net Income

-$738M

Operating Margin

-1.4%

Net Margin

-2.4%

ROE

-7.3%

Total Assets

$34.0B

EPS (Diluted)

$-2.34

Operating Cash Flow

$2.3B

Source: XBRL data from LyondellBasell FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on LyondellBasell

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available